IDEAYA Biosciences Signs Clinical Collaboration with Roche for PRMT5 and pan-RAS Inhibitor Combination in PDAC

Joint governance structures and split supply responsibilities will define how IDEAYA Biosciences and Roche operationalise their new clinical collaboration, a design that places IND sponsorship squarely with IDEAYA while Roche retains GMP obligations for its investigational compound. The two companies will evaluate IDE892, IDEAYA's Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with Roche's Phase 1 pan-RAS inhibitor RG6505, in patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma (PDAC).

IDEAYA will sponsor the combination study; Roche will supply RG6505. A joint governance committee will oversee the trial, a structure that distributes oversight responsibilities across two sponsors, a configuration that QA directors and regulatory affairs leads should map carefully against 21 CFR Part 312 obligations, particularly around IND amendments, safety reporting timelines, and investigational product accountability. Each company retains independent commercial rights to its respective compound, whether as monotherapy or in combination.

The scientific rationale is grounded in co-occurring mutation frequency. MTAP deletion is estimated to occur in up to 40% of PDAC cases, and nearly all MTAP-deleted PDAC tumours carry concurrent RAS mutations. IDE892 has shown monotherapy regressions in MTAP-deleted preclinical models; pairing it with a pan-RAS inhibitor targets a mechanistically complementary vulnerability in a patient population that currently has no approved targeted treatment options.

The collaboration also preserves optionality for a triplet regimen. Upon joint approval by both parties, the agreement allows evaluation of IDE892 and RG6505 alongside IDE397, IDEAYA's Phase 2 MAT2A inhibitor, a combination that would further complicate supply chain coordination and protocol amendment workflows if pursued. IDEAYA is already evaluating IDE892 in a Phase 1 dose escalation study across MTAP-deleted solid tumours, with additional combination cohorts planned in NSCLC and other solid tumour types using IDE397.

For plant heads managing investigational product release, the dual-sponsor supply model warrants early alignment on batch documentation, comparability protocols, and chain-of-custody requirements before combination cohorts open.

Source: IDEAYA Biosciences Newsroom via PR Newswire, 3 June 2026.